Clinical Benefits of Intra-articular Anakinra for Persistent Knee Effusion

 

 Buy Article Permissions and Reprints

ABSTRACT

Postoperative or postinjury inflammation after knee surgery is a significant clinical challenge. Cytokines, particularly interleukin-1 (IL-1), released by inflammatory cells have been shown to have a role in cartilage homeostasis and tissue repair and fibrosis. Anakinra, an IL-1 receptor antagonist (IL-1ra), has shown promising results from its use in treating rheumatoid arthritis, juvenile inflammatory arthritis, and autoimmune inflammatory syndromes. We hypothesized that intra-articular anakinra injection may result in sustained improvements of persistent effusion of the knee joint refractory to other modalities. We retrospectively reviewed 6 patients (3 female, 3 male), ranging in age from 17 to 50 years, who underwent injection of intra-articular anakinra, 200 mg, between November 15, 2007, and April 29, 2010, for persistent effusions of the postoperative knee. All of the patients treated with intra-articular anakinra for persistent effusions failed conservative treatment with physical therapy, oral anti-inflammatory medication, and 4 of 6 patients failed prior corticosteroid injections. After intra-articular anakinra, 66% had improvement in knee arc of motion (15 to 30 degrees) and pain, and 5 of 6 (83%) had improvement in swelling. All of these patients were able to return to sports. We found intra-articular anakinra to be safe and effective in this small group of patients with persistent effusions. There were no adverse clinical reactions or infections. These findings provide support for further study of IL-1 inhibition in the management of postsurgical inflammation.

REFERENCES

• 1 Malemud C J, Islam N, Haqqi T M. Pathophysiological mechanisms in osteoarthritis lead to novel therapeutic strategies.  Cells Tissues Organs. 2003;  174 34-48
  CrossrefPubMedGoogle Scholar
• 2 Shin S J, Fermor B, Weinberg J B, Pisetsky D S, Guilak F. Regulation of matrix turnover in meniscal explants: role of mechanical stress, interleukin-1, and nitric oxide.  J Appl Physiol. 2003;  95 308-313
  CrossrefPubMedGoogle Scholar
• 3 Pelletier J P, McCollum R, Cloutier J M, Martel-Pelletier J. Synthesis of metalloproteases and interleukin 6 (IL-6) in human osteoarthritic synovial membrane is an IL-1 mediated process.  J Rheumatol Suppl. 1995;  43 109-114
  PubMedGoogle Scholar
• 4 Cameron M L, Fu F H, Paessler H H, Schneider M, Evans C H. Synovial fluid cytokine concentrations as possible prognostic indicators in the ACL-deficient knee.  Knee Surg Sports Traumatol Arthrosc. 1994;  2 38-44
  CrossrefPubMedGoogle Scholar
• 5 Iqbal I, Fleischmann R. Treatment of osteoarthritis with anakinra.  Curr Rheumatol Rep. 2007;  9 31-35
  CrossrefPubMedGoogle Scholar
• 6 Burger D, Dayer J M, Palmer G, Gabay C. Is IL-1 a good therapeutic target in the treatment of arthritis?.  Best Pract Res Clin Rheumatol. 2006;  20 879-896
  CrossrefPubMedGoogle Scholar
• 7 Lequerré T, Quartier P, Rosellini D Société Francophone pour la Rhumatologie et les Maladies Inflammatoires en Pédiatrie (SOFREMIP) et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: Preliminary experience in France.  Ann Rheum Dis. 2008;  67 302-308
  PubMedGoogle Scholar
• 8 Céleste C, Ionescu M, Robin Poole A, Laverty S. Repeated intraarticular injections of triamcinolone acetonide alter cartilage matrix metabolism measured by biomarkers in synovial fluid.  J Orthop Res. 2005;  23 602-610
  CrossrefPubMedGoogle Scholar
• 9 Nakazawa F, Matsuno H, Yudoh K, Watanabe Y, Katayama R, Kimura T. Corticosteroid treatment induces chondrocyte apoptosis in an experimental arthritis model and in chondrocyte cultures.  Clin Exp Rheumatol. 2002;  20 773-781
  PubMedGoogle Scholar
• 10 Larsen C M, Faulenbach M, Vaag A, Ehses J A, Donath M Y, Mandrup-Poulsen T. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes.  Diabetes Care. 2009;  32 1663-1668
  CrossrefPubMedGoogle Scholar
• 11 McNulty A L, Moutos F T, Weinberg J B, Guilak F. Enhanced integrative repair of the porcine meniscus in vitro by inhibition of interleukin-1 or tumor necrosis factor alpha.  Arthritis Rheum. 2007;  56 3033-3042
  CrossrefPubMedGoogle Scholar
• 12 Goldring M B, Birkhead J, Sandell L J, Kimura T, Krane S M. Interleukin 1 suppresses expression of cartilage-specific types II and IX collagens and increases types I and III collagens in human chondrocytes.  J Clin Invest. 1988;  82 2026-2037
  CrossrefPubMedGoogle Scholar
• 13 Chevalier X, Giraudeau B, Conrozier T, Marliere J, Kiefer P, Goupille P. Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: A multicenter study.  J Rheumatol. 2005;  32 1317-1323
  PubMedGoogle Scholar
• 14 Bodar E J, van der Hilst J C, Drenth J P, van der Meer J W, Simon A. Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: Introducing a vaccination provocation model.  Neth J Med. 2005;  63 260-264
  PubMedGoogle Scholar
• 15 Reiff A. The use of anakinra in juvenile arthritis.  Curr Rheumatol Rep. 2005;  7 434-440
  CrossrefPubMedGoogle Scholar
• 16 Mirault T, Launay D, Cuisset L et al.. Recovery from deafness in a patient with Muckle-Wells syndrome treated with anakinra.  Arthritis Rheum. 2006;  54 1697-1700
  CrossrefPubMedGoogle Scholar
• 17 Matsubayashi T, Sugiura H, Arai T, Oh-Ishi T, Inamo Y. Anakinra therapy for CINCA syndrome with a novel mutation in exon 4 of the CIAS1 gene.  Acta Paediatr. 2006;  95 246-249
  CrossrefPubMedGoogle Scholar
• 18 Vounotrypidis P, Sakellariou G T, Zisopoulos D, Berberidis C. Refractory relapsing polychondritis: Rapid and sustained response in the treatment with an IL-1 receptor antagonist (anakinra).  Rheumatology (Oxford). 2006;  45 491-492
  CrossrefPubMedGoogle Scholar
• 19 Palmieri-Smith R M, Kreinbrink J, Ashton-Miller J A, Wojtys E M. Quadriceps inhibition induced by an experimental knee joint effusion affects knee joint mechanics during a single-legged drop landing.  Am J Sports Med. 2007;  35 1269-1275
  CrossrefPubMedGoogle Scholar
• 20 Guido Jr J, Voight M L, Blackburn T A, Kidder J D, Nord S. The effects of chronic effusion on knee joint proprioception: A case study.  J Orthop Sports Phys Ther. 1997;  25 208-212
  PubMedGoogle Scholar
• 21 Stolina M, Schett G, Dwyer D et al.. RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: Comparison with anti-TNFalpha or anti-IL-1 therapies.  Arthritis Res Ther. 2009;  11 R187
  CrossrefPubMedGoogle Scholar
• 22 Zeft A, Hollister R, LaFleur B et al.. Anakinra for systemic juvenile arthritis: The Rocky Mountain experience.  J Clin Rheumatol. 2009;  15 161-164
  CrossrefPubMedGoogle Scholar
• 23 Aksentijevich I, Masters S L, Ferguson P J et al.. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist.  N Engl J Med. 2009;  360 2426-2437
  CrossrefPubMedGoogle Scholar
• 24 Ishida Y, Kondo T, Kimura A, Matsushima K, Mukaida N. Absence of IL-1 receptor antagonist impaired wound healing along with aberrant NF-kappaB activation and a reciprocal suppression of TGF-beta signal pathway.  J Immunol. 2006;  176 5598-5606
  PubMedGoogle Scholar
• 25 Graves D T, Nooh N, Gillen T et al.. IL-1 plays a critical role in oral, but not dermal, wound healing.  J Immunol. 2001;  167 5316-5320
  PubMedGoogle Scholar

Christopher BrownM.D. 

Department of Orthopaedics, Duke University Medical Center

Box 3970 DUMC, Durham, NC 27710

Email: christopher.a.brown@duke.edu